Chugai Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations

Chugai Pharmaceutical (TSE:4519) Third Quarter 2024 Results

Key Financial Results

• Revenue: JP¥315.7b (up 22% from 3Q 2023).
• Net income: JP¥109.5b (up 41% from 3Q 2023).
• Profit margin: 35% (up from 30% in 3Q 2023). The increase in margin was driven by higher revenue.
• EPS: JP¥66.54 (up from JP¥47.15 in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Chugai Pharmaceutical Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates by 10%.

Looking ahead, revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Pharmaceuticals industry in Japan.

Performance of the Japanese Pharmaceuticals industry.

The company's shares are down 2.2% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. See our latest analysis on Chugai Pharmaceutical's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.